This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
Trine Lund-Jacobsen
Department of Endocrinology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Corresponding Author
ORCiD: https://orcid.org/0000-0002-3616-5929
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Given that BC patients now live longer and have a higher survival rate, long-term side effects of primary treatment and patients' Life Quality (LQ) have become a more central issue. The purpose of this study was to investigate whether Life Quality changes after primary BC treatment.
Method: A prospective cohort study was conducted including 149 Danish women with BC. Sixty had entered the date since chemotherapy termination and their daily measurement of QoL for mood in the app [email protected] All users can only enter the app with a Danish NemID and own mobile device. The app includes self-reported patient baseline characteristics related to BC treatment and simple self-reported data of LQ measured in mood, social life and wellbeing measured by fatigue, pain and appetite and physical activities.
Results: During the pilot test period, 149 BC survivors entered baseline data. Of the 149 BC survivors 60 (40%) have entered chemotherapy history and LQ data. The mean age of the BC survivors was 58.2 ±9.6 years (range 27-78 years). Days since chemotherapy termination was with a mean of 450 days (range 54-5.175 days). In group A (n=20) 35% reported 0-365 days and in group B (n=39) 65% reported more than 365 days since chemotherapy termination. In the whole group 65% reported neutral mood. By division into group A vs. B showed that mood improve over time measured by several in group B had a neutral mood achieved. Half (53%) had a good social life. Similar changes were reported for pain with 79% reporting mild to moderate pain in the whole group, group A vs. B showed an increasing level of pain over time with 24% reporting moderate to severe pain in group B vs. 13% in group A. Finally, it was observed that 58% reported mild to moderate appetite and it is decreasing over time, 64% reported mild to moderate appetite in group B vs. 50% in group A.
Conclusion: Our results indicate that BC survivors have impaired QoL up to several years after primary BC treatment but there is a trend of some improvement over time.
Trial registration: ClinicalTrials.grov:NCT03784651
Keywords
Health-Related Quality of Life, Life Quality, breast cancer, PRO, ePRO, electronic self-reporting, App, own mobile device, pilot test
Figure 1
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 11 Dec, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Trine Lund-Jacobsen
Department of Endocrinology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Corresponding Author
ORCiD: https://orcid.org/0000-0002-3616-5929
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 11 Dec, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Given that BC patients now live longer and have a higher survival rate, long-term side effects of primary treatment and patients' Life Quality (LQ) have become a more central issue. The purpose of this study was to investigate whether Life Quality changes after primary BC treatment.
Method: A prospective cohort study was conducted including 149 Danish women with BC. Sixty had entered the date since chemotherapy termination and their daily measurement of QoL for mood in the app [email protected] All users can only enter the app with a Danish NemID and own mobile device. The app includes self-reported patient baseline characteristics related to BC treatment and simple self-reported data of LQ measured in mood, social life and wellbeing measured by fatigue, pain and appetite and physical activities.
Results: During the pilot test period, 149 BC survivors entered baseline data. Of the 149 BC survivors 60 (40%) have entered chemotherapy history and LQ data. The mean age of the BC survivors was 58.2 ±9.6 years (range 27-78 years). Days since chemotherapy termination was with a mean of 450 days (range 54-5.175 days). In group A (n=20) 35% reported 0-365 days and in group B (n=39) 65% reported more than 365 days since chemotherapy termination. In the whole group 65% reported neutral mood. By division into group A vs. B showed that mood improve over time measured by several in group B had a neutral mood achieved. Half (53%) had a good social life. Similar changes were reported for pain with 79% reporting mild to moderate pain in the whole group, group A vs. B showed an increasing level of pain over time with 24% reporting moderate to severe pain in group B vs. 13% in group A. Finally, it was observed that 58% reported mild to moderate appetite and it is decreasing over time, 64% reported mild to moderate appetite in group B vs. 50% in group A.
Conclusion: Our results indicate that BC survivors have impaired QoL up to several years after primary BC treatment but there is a trend of some improvement over time.
Trial registration: ClinicalTrials.grov:NCT03784651
Figure 1
Figure 1
Loading...